
Harold J. Burstein, MD, PhD, discusses the most clinically relevant new data on endocrine therapy for early breast cancer from the 2007 San Antonio Breast Cancer Symposium.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the results of recent studies of adjuvant and neoadjuvant chemotherapy for the treatment of breast cancer
- Discuss therapies designed to preserve the musculoskeletal health for women on hormonal therapy
- Describe how CYP2D6 polymorphisms may affect the efficacy of tamoxifen in women with estrogen receptor–positive breast cancer